News Agency
The Times

Pierre Fabre Laboratories receives European Commission Approval for BRAFTOVI®(encorafenib) in combination with MEKTOVI® (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAFV600E mutation

  • Written by PR Newswire
Pierre Fabre Laboratories receives European Commission Approval for BRAFTOVI®(encorafenib) in combination with MEKTOVI® (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAFV600E mutation
  • European approval is based on results from the Phase II PHAROS trial, which showed a meaningful clinical benefit to BRAFV600E mutated advanced NSCLC patients with an objective response rate (ORR) of 75% in treatment-naïve patients and 46% in previously treated patients.[1-3] The safety profile is consistent with that observed...

Read more: Pierre Fabre Laboratories receives European Commission Approval for BRAFTOVI®(encorafenib) in...

Why Shopify Web Development Is Important For Modern Online Stores

A successful online store requires more than attractive product images and basic functionality. Businesses need websites that load quickly, provide smooth navigation, and create a reliable shopping experience across all devices. Professional Shopify web development helps businesses build scalable eCommerce stores... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion